Zurn Elkay's Insider Selling Isn't the Story — The Valuation Is

The insider selling at Zurn Elkay is real — but the factor stack tells a different story than the headline implies.

In February 2026, CEO Todd Adams sold $28.1 million worth of shares at $51–$53, followed within the same two-week window by coordinated selling from the CFO, CTO, president, general counsel, chief accounting officer, and a director. On its face, that looks like the management team exiting together. The reality is more mechanical, but the valuation question the selling accidentally highlights is real.

The Selling Was Mostly Mechanical

The February cluster came immediately after Adams received 569,734 shares from performance awards on February 6. He sold approximately 538,000 of them between February 9–10. The timing — vesting followed by selling within days, at prices just above the $50 area — is the textbook pattern of tax withholding on restricted stock unit (RSU) vesting. RSUs are taxed as ordinary income when they vest, so the company or broker automatically sells a portion to cover the obligation. Typical tax withholding runs 20–40% of the shares, though executives can elect to sell more for diversification.

The other executives — CFO David Pauli, CTO Michael Troutman, president Jeffrey Schoon, and general counsel Jeffrey LaValle — all sold in the same February 4–17 window, which tracks with the same annual performance award cycle. The CAO Mark Peterson's separate sale of 25,000 shares at $53.02 on August 4 is a routine smaller position adjustment.

The mechanical pattern matters because it means the selling doesn't signal a loss of confidence in the business. The executives weren't quietly exiting ahead of bad news — they were working through the annual compensation machinery.

But the Factor Stack Raises a Different Question

Setting aside the selling, the metrics tell a story of strong execution wrapped in a stretched valuation. Revenue grew 10.7% year over year, with quarter-over-quarter acceleration of 13.4%. Gross margin sits at 45.4%, operating margin at 17.1%, and free cash flow growth is up 34.5% year over year. The company has beaten earnings in both Q1 and Q2 of 2026 — Q1 by 13.9%, Q2 by 5.8% on adjusted EPS of $0.50 versus $0.47 consensus. Free cash flow for the trailing twelve months is $378.5 million, with a net debt position of just $134 million against $365 million in cash.

Those are the numbers that would earn a high growth-and-profitability score in any systematic framework.

The problem is the valuation. The stock trades at 30.9 times trailing earnings and 45.3 times forward earnings. Look at the water-industrial peer set:

Ticker	PE (TTM)	EV/EBITDA	PB	PS
ZWS	30.9x	18.9x	5.1x	4.8x
WTS	34.1x	22.4x	6.0x	4.9x
XYL	27.6x	18.5x	2.6x	3.1x
PNR	16.9x	14.8x	2.9x	2.7x
MAS	17.3x	12.1x	—	2.0x

Zurn Elkay is the most expensive of this group on forward earnings. The PEG ratio of 0.51 looks cheap in isolation, but PEG built on trailing growth can mask what the forward PE is really saying: the market is pricing in sustained double-digit earnings growth for years ahead. Any stumble in that trajectory — a quarter that misses, guidance that softens, margin expansion that stalls — and the multiple compresses fast.

AInvest's aggregate signal labels the stock a Hold, which aligns with what the factor stack shows: strong fundamentals running up against valuation that has already done most of the work.

What the Momentum Layer Adds

Technically, the stock is above both its 50-day ($48.82) and 200-day ($48.11) moving averages, with an RSI of 58.3 — neutral territory, not overbought. The stock is up 8.6% over the past 20 days and 10.6% year-to-date, with a rolling annual return of 16.2%. Momentum supports the trend but doesn't signal urgency. The MACD is positive at 0.98, confirming the uptrend is intact but not accelerating aggressively.

The Bottom Line

The insider selling isn't the story. It's a distraction that accidentally points to the real one. The management team isn't fleeing — they're working through the tax obligations on their annual awards, and the business continues to execute with solid revenue growth, margin expansion, and earnings beats.

But at 45 times forward earnings, the stock has priced itself for perfection. That's a forward PE that assumes no quarter will miss, no margin expansion will stall, and no macro headwind — tariffs, input costs, or demand softness — will interrupt the trajectory. The PEG ratio of 0.51 only looks attractive if you trust that the trailing 10.7% revenue growth will persist at that pace or accelerate. The forward multiple says the market already believes it will.

For investors who already own the stock, the factor stack doesn't demand a sell. The growth, profitability, and balance sheet are genuine strengths. But for anyone considering a new position at $51, the valuation premium to peers means you're paying a price that leaves little room for error. The trigger to reconsider isn't the insider selling — it's a quarter where the earnings beat narrows, guidance flattens, or margins stop expanding. That's when the 45x forward multiple starts looking expensive rather than justified.